Author: Admin

Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

From Startup Sophiris Bio Link to Full Article: http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2018-financial-results-and SAN DIEGO and VANCOUVER, British Columbia, Nov. 13, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases,

AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update

From Startup Avrobio Link to Full Article: During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to

Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates

From Startup Synlogic Tx Link to Full Article: – Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019 – – Ongoing clinical trials of SYNB1020 and SYNB1618 in patients with data expected in 2019 – – Management to host

Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-third-quarter-2018-financial-results-and Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to announce data from interim analysis of exploratory fibromyalgia study in December 2018 EVANSTON, Ill.,

Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team

From Startup Sigilon Therapeutics Link to Full Article: http://sigilon.com/2018/11/13/sigilon-therapeutics-announces-appointment-of-four-new-members-of-senior-management-team/ CAMBRIDGE, Mass. — Nov. 13, 2018 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its

Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

From Startup Neon Therapeutics Link to Full Article: Data presented at ESMO and SITC underscore continued clinical progress across platform and pipeline CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results and provided a business update

Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update

From Startup Urovant Link to Full Article: https://urovant.com/2018/11/12/urovant-sciences-reports-financial-results-for-the-second-fiscal-quarter-ended-september-30-2018-and-provides-corporate-update/ BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 12, 2018– Urovant Sciences Ltd. (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates. Recent Business Highlights Completed enrollment in international

U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/us-surgeon-general-jerome-adams-discusses-opioid-alternatives SAN DIEGO, Nov. 12, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside

Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

From Startup Synlogic Tx Link to Full Article: – Data support ongoing evaluation of Synthetic BioticTM SYNB1020 for the potential treatment of hyperammonemia – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2018– Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today